S. A. Rawlings

Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains

This study evaluates a multivalent mRNA vaccine encoding SARS-CoV-2 and SARS-CoV receptor-binding domains, showing it induces cross-neutralizing antibodies against multiple variants in mice.

Persistent Immune and Clotting Dysfunction Detected in Saliva and Blood Plasma after COVID-19

The paper identifies persistent immune and clotting dysfunction in saliva and plasma of COVID-19 patients 4-6 weeks post-symptom resolution, highlighting saliva as a viable alternative to plasma for monitoring immune and inflammatory sequelae.

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease

The paper identifies broadly neutralizing antibodies targeting the S2 region of betacoronavirus spikes that protect against SARS-CoV-1, SARS-CoV-2, and MERS-CoV.

Distinguishing COVID-19 infection and vaccination history by T cell reactivity

This study develops a T cell-based method to distinguish between SARS-CoV-2 infection and vaccination by analyzing T cell reactivity to specific epitopes, achieving high classification accuracy across different groups.

Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses

This study isolates a panel of broadly neutralizing antibodies against SARS-like viruses from donors, showing effectiveness against multiple variants including Omicron.

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques

This study shows that rhesus macaques can be immunized to produce broadly neutralizing antibodies against multiple SARS-related viruses, highlighting differences in B cell repertoires between humans and macaques.

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

This study identifies a broadly neutralizing antibody that targets a conserved site on beta-coronavirus spike proteins and provides protection against SARS-CoV-2 infection.

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.

The paper analyzes T cell responses to SARS-CoV-2 variants and finds minimal impact on CD4+ and CD8+ T cell reactivity in convalescents and vaccinees.

Immunological memory to SARS-CoV-2 assessed for up to eight months after infection

The paper assesses SARS-CoV-2 immune memory components over eight months post-infection, finding varying kinetics in antibodies, B cells, and T cells.

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

This study rapidly identifies potent SARS-CoV-2 neutralizing antibodies and demonstrates their protective efficacy in an animal model.